European Journal of Histochemistry https://www.ejh.it:443/index.php/ejh <p>The <strong>European Journal of Histochemistry&nbsp;</strong>has been an influential cytology journal for over 60 years, publishing research articles on functional cytology and histology in animals and plants. The&nbsp;<strong>European Journal of Histochemistry&nbsp;</strong>offers original research articles investigating on structural and molecular components performed by histochemical and immunohistochemical methods, at light and electron microscopy, cytometry and imaging techniques.</p> <p>Areas of particular interest include cell differentiation, senescence and death, and cell-cell interactions in normal and pathological tissues; attention is also given to articles on newly developed or originally applied histochemical and microscopical techniques.</p> <p>Since its foundation in 1954,&nbsp;the <strong>European Journal of Histochemistry&nbsp;</strong>is the official organ of the Italian Society of Histochemistry.</p> <p>&nbsp;</p> <h3>Submissions open for the Special Collection "<a href="https://www.ejh.it/index.php/ejh/fort_special_issue" target="_blank" rel="noopener"><strong>Advances in neuromorphology in health and disease</strong></a>"</h3> <p>Neuroscience is constantly expanding, and experiments are performed thanks to a wide variety of techniques starting from the cellular and animal level, to the human level. All the different approaches are based on the consolidated awareness that, in the nervous system, the structural organization is entirely and intimately linked to function. This is one of the reasons why neuromorphology is a continuously developing field where new techniques are developed to better explore the cellular organization and anatomical structure of the nervous system, in the attempt to elucidate their relation with functions in health and disease.&nbsp;<br>The focus of this special issue is to illustrate the current progress on new approaches to the study of the central and peripheral nervous system and the physio-pathological correlations therein.<br>Contributions may range from novel microscopical and histochemical methods to the application of established techniques in neuroscience and in animal or cellular models of neurological diseases, including studies investigating the correlation of environment and plasticity of neural circuits.</p> <p>The deadline for manuscript submission is&nbsp;<strong>April 30, 2021</strong>.</p> en-US <p><strong>PAGEPress</strong> has chosen to apply the&nbsp;<a href="http://creativecommons.org/licenses/by-nc/4.0/" target="_blank" rel="noopener"><strong>Creative Commons Attribution NonCommercial 4.0 International License</strong></a>&nbsp;(CC BY-NC 4.0) to all manuscripts to be published.<br><br>An Open Access Publication is one that meets the following two conditions:</p> <ol> <li class="show">the author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.</li> <li class="show">a complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.</li> </ol> <p>Authors who publish with this journal agree to the following terms:</p> <ol> <li class="show">Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</li> <li class="show">Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.</li> <li class="show">Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.</li> </ol> nadia.moscato@pagepress.org (Nadia Moscato) tiziano.taccini@pagepress.org (Tiziano Taccini) Wed, 20 Jan 2021 13:39:26 +0000 OJS 3.1.2.4 http://blogs.law.harvard.edu/tech/rss 60 Immunopositivity for Siglec-15 in gastric cancer and its association with clinical and pathological parameters https://www.ejh.it:443/index.php/ejh/article/view/3174 <p>The sialic acid-binding immunoglobulin-type lectin Siglec-15 is a promising target to cancer immunotherapy in several tumor types. The present study aimed to investigate Siglec-15 expression in gastric cancer (GC) patient tissue and to evaluate its clinical value. Siglec-15 expression was evaluated by immunohistochemistry with 71 patients. Siglec-15 staining was observed in tumor cells of 53 (74.64%) patients, with significant association with histologic classification and angiolymphatic invasion (p&lt;0.05). Immunohistochemistry analysis also detected Siglec-15 in tumor-associated stroma cells (macrophages/myeloid cells). There was no significant association with outcomes parameters. Siglec-15 expression in well differentiated histological GC tissues and in the tumor microenvironment are potential targets to be further investigated as a novel prognostic factor for GC.</p> Michael Williams Leal Quirino, Michelly Cristiny Pereira, Maria de Fátima Deodato de Souza, Ivan da Rocha Pitta, Antônio Felix da Silva Filho, Mario S. de Souza Albuquerque, Amanda Pinheiro de Barros Albuquerque, Mário Rino Martins, Maira Galdino da Rocha Pitta, Moacyr Jesus Barreto de Melo Rêgo Copyright (c) 2021 The Author(s) http://creativecommons.org/licenses/by-nc/4.0 https://www.ejh.it:443/index.php/ejh/article/view/3174 Thu, 04 Mar 2021 08:28:01 +0000 New bitongling (NBTL) ameliorates rheumatoid arthritis in rats through inhibiting JAK2/STAT3 signaling pathway https://www.ejh.it:443/index.php/ejh/article/view/3202 <p>Rheumatoid arthritis (RA) is featured by a variety of physical symptoms and fibroblast-like synoviocytes (FLSs) abnormal proliferation. Increasing evidence has demonstrated that traditional Chinese medicine exerts an important role in RA treatment. New bitongling (NBTL) as one of the traditional Chinese medicine has been reported to be involved in the progression of RA, but the exact mechanism is unclear. In our study, we intended to investigate the effect of NBTL on RA to identify the mechanisms related to JAK2/STAT3 signaling pathway. Extracts of <em>Tripterygium wilfordii</em> (TW), a traditional Chinese herbal medicine, have been widely used for treating RA in China for several decades, so, TW was used as a positive control drug for TBNL. RA rats were constructed by immunization with collagen type II to evaluate the action of NBTL <em>in vivo</em>. Body weight and arthritic index were evaluated. Hematoxylin and Eosin staining was performed to analysis the morphological changes of ankle joints tissue. TUNEL and flow cytometry were performed to examine cell apoptosis, while CCK8 and Ethynyl-2′-deoxyuridine (EdU) were performed to examine cell proliferation. In addition, the markers of inflammation were detected by Western blot, ELISA, and RT-qPCR. Firstly, we find that rats treated with NBTL or TW not only reduced swelling degree and bone destruction, but also repressed IL-1 β and IL-6 levels. In addition, NBTL and TW could increase the weight of rats, and promote the level of IL-10 and IL-4 <em>in vivo</em>. Furthermore, NBTL inhibited inflammation of FLS, induced cell apoptosis and hindered cell proliferation, which was reversed by dipeptidyl peptidase (DPP), a JAK2/STAT3 pathway activator. Taken together, NBTL potentially retarded RA <em>via</em> JAK2/STAT3 pathway, highlighting novel mechanisms associated with RA.</p> Xiang Li, Yu Xie, An Kang, Yue Wang Copyright (c) 2021 The Author(s) http://creativecommons.org/licenses/by-nc/4.0 https://www.ejh.it:443/index.php/ejh/article/view/3202 Wed, 17 Feb 2021 00:00:00 +0000 Effects of rutin on osteoblast MC3T3-E1 differentiation, ALP activity and Runx2 protein expression https://www.ejh.it:443/index.php/ejh/article/view/3195 <p>As a flavonoid, rutin has been found to have a wide range of biological functions, such as resisting inflammation and oxidation, and preventing cerebral hemorrhage and hypertension. It has been found to play an important role in osteoporosis and other orthopedic diseases in recent years. MC3T3-E1 cells were randomly divided into a control group, a rutin-1 group (0.01 mmol/L), a rutin-2 group (0.05 mmol/L) and a rutin-3 group (0.1 mmol/L). Osteogenic differentiation of cells was induced by osteogenic induction fluid. The control group was treated with the maximum dose of drug solvent. 2~3 days later, the solvent was replaced with fresh osteogenic induction fluid containing rutin. After a certain period of routine culture, the cells were collected for subsequent experiments. The expression of <em>Runx2</em> gene in cells in all groups was detected by Real-time PCR; the expression of Runx2 protein was detected by Western blot and immunocytochemistry; the activity of ALP was detected by reagent kit method; osteogenic differentiation was analyzed by alizarin red staining. The results of Real-time PCR showed that, compared with the control group, the treatment of cells with rutin can significantly increase the expression of <em>Runx2</em> gene (p&lt;0.05); the higher the concentration, the higher the expression of <em>Runx2</em> gene, and significant differences were found among groups in which different concentrations were used (p&lt;0.05); the results of Western blot and IHC showed that the expression trend of Runx2 protein in each group was consistent with PCR results. In drug treatment groups, the activity of ALP was significantly higher than that in the control group (p&lt;0.05); there were significant differences among groups in which different concentrations were used (p&lt;0.05). The results of alizarin red staining showed that calcified nodules were formed in all groups and that the area of calcified nodules formed in groups treated with rutin was greater than that in the control group; the greater the concentration, the larger the area. Rutin can promote osteoblastic differentiation; and the greater the concentration, the more effective it is.</p> Xin-Wei Liu, Bin Ma, Ying Zi, Liang-Bi Xiang, Tian-Yu Han Copyright (c) 2021 The Author(s) http://creativecommons.org/licenses/by-nc/4.0 https://www.ejh.it:443/index.php/ejh/article/view/3195 Wed, 20 Jan 2021 13:32:43 +0000 Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances https://www.ejh.it:443/index.php/ejh/article/view/3173 <p>As the leading malignancy among women, breast cancer is a serious threat to the life and health of women. In this context, it is of particular importance that a proper therapeutic target be identified for breast cancer treatment. We collected the pathological tissues of 80 patients, with the view to discovering appropriate molecular targets for the treatment of breast cancer, this paper analyzes the expressions of ZNF436, β-catenin, EGFR and CMTM5 in breast cancer tissues, as well as their correlations with breast cancer in combination with the clinicopathologic characteristics of studied patients. Immunohistochemistry (IHC) was utilized to detect the expression levels of ZNF436, β-catenin, EGFR and CMTM5 in cancerous and paracancerous tissues of breast cancer patients. The expression levels of ZNF436, β-Catenin and EGFR in breast cancer tissues were significantly greater than those in paracancerous tissues in this study (p&lt;0.05), while CMTM5 was highly expressed in paracancerous tissues (p&lt;0.05). Additionally, the correlation of the expressions of such indicators with the staging, differentiation and lymphatic metastasis of breast cancer, were also found to be statistically significant at the level p&lt;0.05. The different expression levels of ZNF436, β-catenin, EGFR and CMTM5 in breast cancer and paracancerous tissues open up the possibility of utilizing them as molecular markers for breast cancer. These findings provide a theoretical basis for targeted molecular therapies for breast cancer, and hence carry a significant practical significance.</p> Zhi Chen, Na Cui, Ji-sen Zhao, Jian-fei Wu, Fang Ma, Cong Li, Xian-yi Liu Copyright (c) 2021 The Author(s) http://creativecommons.org/licenses/by-nc/4.0 https://www.ejh.it:443/index.php/ejh/article/view/3173 Wed, 20 Jan 2021 13:38:50 +0000 miR-26b regulates cell proliferation and apoptosis of CD117+CD44+ ovarian cancer stem cells by targeting PTEN https://www.ejh.it:443/index.php/ejh/article/view/3186 <p>Ovarian cancer (OC) is the one of the most common cancer in women globally. However, it still represents the most dangerous gynecologic malignancy even with the advances in detection and therapeutics. Thus, there is an urgent need in finding more effective therapeutic options for OC patients including cancer stem cells (CSC). MicroRNAs (miRNAs) are small, endogenous, and non-coding RNAs that play critical roles in the progression of various types of tumor. Our aim of this study was to find the regulatory function of microRNA-26 (miRNA-26b) on the cell proliferation and apoptosis of ovarian CSCs. Our studies show that miR-26b is under-regulated in human CD117+CD44+ ovarian CSCs. The miR-26b overexpression inhibits the cell proliferation and promotes cell apoptosis. Moreover, phosphatase and tensin homolog (PTEN) is found to be a functional target of miR-26b. Moreover, PTEN overexpression reversed the effects of miR-26b on the cell proliferation and apoptosis. PTEN overexpression remarkably accelerated the cell proliferation, and inhibited cell apoptosis. These results indicate that miR-26b regulates cell proliferation and apoptosis of CD117+CD44+ ovarian CSCs by targeting PTEN.&gt;</p> Zubiao Gao, Xiaofeng Ye, Anne Bordeaux, Stanka Hettich, Siyao Lin, Fang Han, Yan Jia Copyright (c) 2021 The Author(s) http://creativecommons.org/licenses/by-nc/4.0 https://www.ejh.it:443/index.php/ejh/article/view/3186 Thu, 04 Feb 2021 14:54:05 +0000 Study on <em>CCDC69</em> interfering with the prognosis of patients with breast cancer through PPAR signal pathway https://www.ejh.it:443/index.php/ejh/article/view/3207 <p>Coiled-coil domain-containing protein 69 (<em>CCDC69</em>) is a novel gene and limited knowledge in known in breast cancer. In the present study, we aimed to explore the relationship between <em>CCDC69</em> and breast cancer, demonstrate the clinicopathological significance and prognostic role of <em>CCDC69</em> in breast cancer, and analyze the possible mechanism of <em>CCDC69</em> affecting the prognosis of breast cancer. First, from GEO database, TIMER, GEPIA, and OncoLnc, we select <em>CCDC69</em> as the potential gene which closely involved in breast cancer progression. Next, by real-time PCR detection, the expression of <em>CCDC69</em> in breast cancer tissue was notably lower than that in normal breast tissues (p=0.0002). In addition, our immunohistochemistry (IHC) indicated that the positive expression rate of <em>CCDC69</em> in the triple-negative breast cancer (TNBC) was lower than that in the non-TNBC (p=0.0362), and it was negatively correlated with the expression of Ki67 (p=0.001). Further enrichment analysis of <em>CCDC69</em> and the similar genes performed on FunRich3.1.3 revealed that these genes were significantly associated with fat differentiation, and most of them were related to peroxisome proliferator-activated receptor (PPAR) signal pathway. Collectively, our findings suggest that <em>CCDC69</em> is down regulated in breast cancer tissue especially in TNBC which has higher malignant grade and poorer clinical prognosis.</p> Jinjiao Li, Panshi Zheng, Yun Xia Copyright (c) 2021 The Author(s) http://creativecommons.org/licenses/by-nc/4.0 https://www.ejh.it:443/index.php/ejh/article/view/3207 Mon, 22 Feb 2021 13:22:43 +0000